Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107232 | 0.94 | LMNA (0.47) | EPHX2L3MBTL1TDP1LMNAKDM4E | |
| SCHEMBL25308442 | 0.90 | EPHX2 (0.55) | EPHX2L3MBTL1TDP1LMNAKDM4E | |
| SCHEMBL6508631 | 0.88 | ALDH1A1 (0.49) | EPHX2L3MBTL1TDP1LMNAKDM4E | |
| SCHEMBL12147930 | 0.88 | EPHX2 (0.53) | EPHX2L3MBTL1TDP1LMNAKDM4E | |
| SCHEMBL26115850 | 0.87 | EPHX2 (0.53) | EPHX2L3MBTL1TDP1LMNAKDM4E | |
| SCHEMBL10081325 | 0.86 | EPHX2 (0.57) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL25269510 | 0.86 | EPHX2 (0.57) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL19032713 | 0.86 | EPHX2 (0.57) | EPHX2L3MBTL1TDP1FAAHHTT | |
| SCHEMBL31260990 | 0.86 | EPHX2 (0.47) | EPHX2L3MBTL1ALDH1A1NAAA | |
| SCHEMBL13041145 | 0.85 | ALDH1A1 (0.47) | EPHX2L3MBTL1TDP1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751126-B1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1751126-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-7074822-B2 | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005080366-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | PNLIP, CEL, LIPE | EPHX2 1416/4885L3MBTL1 2075/4885TDP1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.